{"entity":{"id":"paper-timbergen-eur-j-cancer","kind":"paper","name":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","aka":[],"tldr":"Paper cited by one cancer page, indexed on Europe PMC as PubMed record 32738571 and published in European Journal of Cancer; the citing page links this DOI, which is how the record was matched.","summary":"Background: This study evaluates the results of the active surveillance (AS) approach in adult patients with desmoid-type fibromatosis (DTF) because AS is advocated as a front-line approach for DTF in the European consensus guidelines.\n\nMethods: A systematic literature search was conducted (December 19th, 2019, updated on April 14th, 2020). Studies describing the outcomes of the AS approach were included. The PRISMA guidelines were used.\n\nResults: Twenty-five articles were included for data retrieval. Forty-two percent of reported patients (1480 of 3527 patients) received AS, the majority were women and the majority had a primary tumour. The median age at diagnosis ranged from 28 to 59 years. Common tumour sites were the extremities/girdles (n = 273), the abdominal wall (n = 253) and the trunk (n = 153). The median reported percentage of progressive disease, stable disease and partial response was 20% (interquartile range [IQR]: 13-35%), 59% (IQR: 37-69%) and 19% (IQR 3-23%), respectively. In 640 patients, the outcome was not specified. The median reported percentage of shifting to an active form of treatment was 29%, most commonly to systemic treatment (n = 195) and surgery (n = 107). The reported median follow-up time ranged between 8 and 73 months. The reported median time to progression and/or initiation of the subgroup shifting from AS to 'active' therapy ranged from 6.3 months to 19.7 months.\n\nConclusion: The majority of patients undergoing AS have either stable disease or a partial response, and about one-third of patients shift to an active form of treatment. Selecting patients who will benefit from active surveillance upfront should be the priority of future studies.\n\nIndexed on Europe PMC as PubMed record 32738571 (DOI 10.1016/j.ejca.2020.06.022). Matched by DOI alone: one cancer page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Eur J Cancer 2020","url":"https://doi.org/10.1016/j.ejca.2020.06.022"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32738571/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/32738571"}],"tags":["europepmc-ingest"],"related":["desmoid-tumour"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-journal-of-cancer"],"dependsOn":[],"notes":[],"journal":"European Journal of Cancer","year":2020,"doi":"10.1016/j.ejca.2020.06.022","pmid":"32738571","authors":"Timbergen MJM, Schut AW, Grünhagen DJ, et al.","paperType":"review","findings":[],"whatItMeans":"One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-timbergen-eur-j-cancer/","neighbours":{"cancer":[{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/"}],"journal":[{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/"}]}}